FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311800913> ?p ?o ?g. }

• W4311800913 endingPage "118" @default.
• W4311800913 startingPage "110" @default.
• W4311800913 abstract "In pediatric practice, the prevalence of rhinosinusitis (RS) depends on age: so, in the age category of 6-7 years old, acute RS at least 1 time per year old affects 8.5% of children, and at the age of 13-14 years old - 14.6%. Acute RS is one of the most common reasons for prescribing antibiotics, so correct treatment is extremely important, given the global crisis of antibiotic resistance. The tactics of treatment of acute RS depends on the form, nature of the inflammatory process and the presence of complications. Purpose - to study the effectiveness of the plant-based dietary supplement Nasirus Sinus syrup in the complex therapy of children 3-11 years old with acute viral and postviral RS. Materials and methods. Were analyzed medical data of 1176 children 3-11 years old who received outpatient therapy with a clinical diagnosis of “Acute viral RS” and “Acute postviral RS” (ICD-10: J01.9). The difference between these patients was only the duration of the disease. Results. It has been established that the use of a plant-based dietary supplement Nasirus Sinus syrup in the complex therapy of children 3-11 years with acute RS helps to reduce subjective (nasal congestion, difficulty in nasal breathing, cough, snoring) and objective (mucous membrane hyperemia, postnasal drainage, rhinorrhea, wheezing, goopiness) manifestations of acute RS in a shorter time compared to the control group. The assessment of the severity of acute viral and postviral RS by Major Sinusitis Severity in absolute numbers in the main group was significantly different from the control group. Conclusions. When using the complex therapy of acute viral and postviral RS in children 3-11 years with the inclusion of a plant-based dietary supplement Nasirus Sinus syrup, the results indicate a decrease in the manifestation of symptoms already on the 3rd day of therapy, reliably demonstrates positive dynamics on the 5th and 7th days. Nasirus Sinus syrup should be recommended for use in children in the complex therapy of RS. The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of all participating institutions. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors." @default.
• W4311800913 created "2022-12-28" @default.
• W4311800913 creator A5024856344 @default.
• W4311800913 creator A5071071554 @default.
• W4311800913 creator A5088502495 @default.
• W4311800913 creator A5091044475 @default.
• W4311800913 date "2022-10-29" @default.
• W4311800913 modified "2023-09-26" @default.
• W4311800913 title "Results of the analysis of epidemiological study of medical data on the effectiveness of Nasirus Sinus syrup in the complex therapy of acute viral and postviral rhinosinusitis in children" @default.
• W4311800913 doi "https://doi.org/10.15574/sp.2022.126.110" @default.
• W4311800913 hasPublicationYear "2022" @default.
• W4311800913 type Work @default.
• W4311800913 citedByCount "0" @default.
• W4311800913 crossrefType "journal-article" @default.
• W4311800913 hasAuthorship W4311800913A5024856344 @default.
• W4311800913 hasAuthorship W4311800913A5071071554 @default.
• W4311800913 hasAuthorship W4311800913A5088502495 @default.
• W4311800913 hasAuthorship W4311800913A5091044475 @default.
• W4311800913 hasBestOaLocation W43118009131 @default.
• W4311800913 hasConcept C126322002 @default.
• W4311800913 hasConcept C141071460 @default.
• W4311800913 hasConcept C187212893 @default.
• W4311800913 hasConcept C2777768476 @default.
• W4311800913 hasConcept C2777844070 @default.
• W4311800913 hasConcept C2778311950 @default.
• W4311800913 hasConcept C2779699568 @default.
• W4311800913 hasConcept C501593827 @default.
• W4311800913 hasConcept C71924100 @default.
• W4311800913 hasConcept C86803240 @default.
• W4311800913 hasConcept C89423630 @default.
• W4311800913 hasConceptScore W4311800913C126322002 @default.
• W4311800913 hasConceptScore W4311800913C141071460 @default.
• W4311800913 hasConceptScore W4311800913C187212893 @default.
• W4311800913 hasConceptScore W4311800913C2777768476 @default.
• W4311800913 hasConceptScore W4311800913C2777844070 @default.
• W4311800913 hasConceptScore W4311800913C2778311950 @default.
• W4311800913 hasConceptScore W4311800913C2779699568 @default.
• W4311800913 hasConceptScore W4311800913C501593827 @default.
• W4311800913 hasConceptScore W4311800913C71924100 @default.
• W4311800913 hasConceptScore W4311800913C86803240 @default.
• W4311800913 hasConceptScore W4311800913C89423630 @default.
• W4311800913 hasIssue "6(126)" @default.
• W4311800913 hasLocation W43118009131 @default.
• W4311800913 hasLocation W43118009132 @default.
• W4311800913 hasOpenAccess W4311800913 @default.
• W4311800913 hasPrimaryLocation W43118009131 @default.
• W4311800913 hasRelatedWork W122820972 @default.
• W4311800913 hasRelatedWork W1887898806 @default.
• W4311800913 hasRelatedWork W2066887349 @default.
• W4311800913 hasRelatedWork W2072495699 @default.
• W4311800913 hasRelatedWork W2087305135 @default.
• W4311800913 hasRelatedWork W2326669311 @default.
• W4311800913 hasRelatedWork W2336783208 @default.
• W4311800913 hasRelatedWork W2913158786 @default.
• W4311800913 hasRelatedWork W3161157860 @default.
• W4311800913 hasRelatedWork W3187507478 @default.
• W4311800913 isParatext "false" @default.
• W4311800913 isRetracted "false" @default.
• W4311800913 workType "article" @default.